VL-NL-02
Dietary SupplementTwo capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
NCT Number: NCT06056258
The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages.
48 participants are expected to be randomized in a ratio of 1:1 to receive either VL-NL-02 or placebo and will be assigned a unique randomization code. Each group will have at least 20 completed participants after accounting for a dropout/withdrawal rate of 17%. The intervention duration for all the study participants is 21 days.
Participants will be asked to fill multiple questionnaires to assess sleep quality and mood imbalance.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
BAJ RR Hospital, Dombivali, Maharashtra, India
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
Time frame: Day 1 of intervention
The Insomnia Severity Index has seven questions that indicates insomnia without clinical significance. The scores of 0-7 determines no clinically significant insomnia, 8-14 determines sub threshold insomnia, 15-21 has moderate severity which determines clinical insomnia and lastly 22-28 has severe insomnia. For each question, participant will be asked to circle or mark the number that best correlates with their sleep quality in the past two weeks. An increase in score will determine the severity of the insomnia.
Time frame: Day 11 of intervention
The Insomnia Severity Index has seven questions that indicates insomnia without clinical significance. The scores of 0-7 determines no clinically significant insomnia, 8-14 determines sub threshold insomnia, 15-21 has moderate severity which determines clinical insomnia and lastly 22-28 has severe insomnia. For each question, participant will be asked to circle or mark the number that best correlates with their sleep quality in the past two weeks. An increase in score will determine the severity of the insomnia.
Time frame: Day 22 of intervention
The Insomnia Severity Index has seven questions that indicates insomnia without clinical significance. The scores of 0-7 determines no clinically significant insomnia, 8-14 determines sub threshold insomnia, 15-21 has moderate severity which determines clinical insomnia and lastly 22-28 has severe insomnia. For each question, participant will be asked to circle or mark the number that best correlates with their sleep quality in the past two weeks. An increase in score will determine the severity of the insomnia.
Time frame: Day 1, 11 and 22 of intervention
It is a mood scale consisting of 16 mood adjectives to which a person responds. Four sub scores can be computed from the BMIS: Pleasant-Unpleasant, Arousal-Calm, Positive-Tired and Negative-Relaxed Mood.
Time frame: Day 1, 11 and 22 of intervention
The DSEA questionnaire has two subscales: Sleep anxiety and Dream emotional scale.
Time frame: Day 1, 11 and 22 of intervention
RSQ-W is a validated scale for measuring refreshing quality of sleep. It has 9 items with answers scaled from 1 to 5. The questionnaire asks about how one felt after waking up and starting the day during the past seven days.
Time frame: Day 1, 11 and 22 of intervention
The SF-36 includes multi-item scales to measure the following 8 dimensions (refer 15.2 for questionnaire):
PF- Physical functioning (10 items in question 3) RP- Role limitations due to physical health problems (4 items in question 4) BP- Overall body pain (questions 7 and 8) SF- Social functioning (questions 6 and 10) MH - General mental health, covering psychological distress and well-being (5 items: questions 9 b, c, d, f and h) RE- Role limitations due to emotional problems (questions 5 a, b and c) VT- Vitality, energy or fatigue (4 items: questions 9 a, e, g and i) GH- General health perceptions (5 items: questions 1 and 11 a to d)
Time frame: Day 0, 10 and 21 of intervention
Polysomnography refers to a systematic process used to collect physiologic parameters during sleep. Sleep stage scoring and detection of arousals for each 30-s epoch will be performed visually according to standard AASM procedures.
Time frame: Day 1 and 22 of Intervention
Normal ranges for cortisol are:
Morning hours 8 10 a.m.: < 19.1 nmol/L (< 0.690 μg/dL) Afternoon hours 2:30-3:30 p.m.: < 11.9 nmol/L (< 0.430 μg/dL)
Time frame: Day 1 and 22 of Intervention
The normal range is 50 to 200 ng/mL (0.28 to 1.14 µmol/L) in healthy individuals
Time frame: Day 1 and 22 of Intervention
The highest levels of melatonin are recorded from 3am onwards with a value of 47.35 pg/ml
Time frame: Day 1 and 22 of Intervention
Vedic Lifesciences Pvt. Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy of VL-NL-02 on Sleep and Mood.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05956886
Dyssomnias, Glucose Metabolism Disorders
Newark, Delaware, United States
View Trial DetailsNCT07277101
Autism Spectrum Disorder, Autistic Disorder
Shanghai, China
View Trial DetailsNCT03665337
Delayed Sleep Phase, Dyssomnias
San Francisco, California, United States
View Trial DetailsNCT06685965
Dyssomnias, Mental Disorders
Zurich, Canton of Zurich, Switzerland
View Trial Details